{
  "version": "1.1.0",
  "description": "HIV-specific prescribing cascade modifiers and ARV-related adverse drug events",
  "last_updated": "2025-01-01",
  "disclaimer": "For decision support only. HIV pharmacology is complex; always consult current HIV guidelines.",
  "art_related_cascades": [
    {
      "id": "VIH001",
      "name_es": "IP/r o INSTI (DTG/BIC) → Dislipidemia → Estatina",
      "name_en": "PI/r or INSTI (DTG/BIC) → Dyslipidemia → Statin",
      "index_drug_class": "Boosted PI / INSTI",
      "index_drugs_examples": ["lopinavir/ritonavir", "darunavir/ritonavir", "darunavir/cobicistat", "dolutegravir", "bictegravir"],
      "ade_mechanism_es": "IP/r: activación de SREBP, inhibición de CYP3A4 → hiperlipidemia. INSTI: ganancia de peso → dislipidemia secundaria.",
      "ade_mechanism_en": "PI/r: SREBP activation, CYP3A4 inhibition → hyperlipidemia. INSTI: weight gain → secondary dyslipidemia.",
      "ade_es": "Hipertrigliceridemia, hipercolesterolemia, dislipidemia mixta",
      "ade_en": "Hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia",
      "cascade_drug_class": "Statin",
      "cascade_drugs_examples": ["rosuvastatin", "pravastatin", "atorvastatin", "pitavastatin"],
      "contraindicated_cascade_drugs": ["simvastatin", "lovastatin"],
      "plausibility": "high",
      "time_to_ade_typical_days_min": 30,
      "time_to_ade_typical_days_max": 365,
      "evidence_level": "A",
      "ddi_warning_es": "ATENCIÓN: Simvastatina y lovastatina están CONTRAINDICADAS con IP/r (riesgo de rabdomiólisis por inhibición CYP3A4). Preferir rosuvastatina, pravastatina o pitavastatina.",
      "ddi_warning_en": "WARNING: Simvastatin and lovastatin are CONTRAINDICATED with PI/r (rhabdomyolysis risk via CYP3A4 inhibition). Prefer rosuvastatin, pravastatin, or pitavastatin.",
      "clinical_note_es": "Verificar el tipo específico de estatina prescrita. El cambio a un ARV con mejor perfil lipídico puede ser más apropiado que añadir estatina.",
      "clinical_note_en": "Verify the specific statin prescribed. Switching to an ARV with better lipid profile may be more appropriate than adding a statin.",
      "references": ["DHHS Guidelines 2024", "Panel on Antiretroviral Guidelines for Adults and Adolescents 2024"]
    },
    {
      "id": "VIH002",
      "name_es": "Tenofovir DF (TDF) → Nefrotoxicidad → Correcciones de dosis / Nuevos medicamentos renales",
      "name_en": "Tenofovir DF (TDF) → Nephrotoxicity → Dose corrections / New renal drugs",
      "index_drug_class": "NRTI (Tenofovir)",
      "index_drugs_examples": ["tenofovir disoproxil fumarate", "TDF"],
      "ade_mechanism_es": "Acumulación mitocondrial en túbulo proximal → disfunción tubular proximal → síndrome de Fanconi, disminución TFGe",
      "ade_mechanism_en": "Mitochondrial accumulation in proximal tubule → proximal tubular dysfunction → Fanconi syndrome, eGFR decline",
      "ade_es": "Disfunción renal tubular, disminución de TFGe, hipofosfatemia, proteinuria",
      "ade_en": "Renal tubular dysfunction, eGFR decline, hypophosphatemia, proteinuria",
      "cascade_drug_class": "Phosphate supplements / Renal monitoring drugs",
      "cascade_drugs_examples": ["sodium phosphate", "potassium phosphate", "dose-adjusted medications"],
      "plausibility": "high",
      "time_to_ade_typical_days_min": 90,
      "time_to_ade_typical_days_max": 730,
      "evidence_level": "A",
      "clinical_note_es": "Preferir TAF (tenofovir alafenamida) sobre TDF en pacientes con factores de riesgo renal. Monitorizar función renal periódicamente.",
      "clinical_note_en": "Prefer TAF (tenofovir alafenamide) over TDF in patients with renal risk factors. Monitor renal function periodically.",
      "references": ["Mocroft A et al. Clin Infect Dis 2010", "DHHS Guidelines 2024"]
    },
    {
      "id": "VIH003",
      "name_es": "INSTI (DTG/BIC/RAL) + TDF → Ganancia de peso → Antidiabético/Antihipertensivo",
      "name_en": "INSTI (DTG/BIC/RAL) + TDF → Weight Gain → Antidiabetic/Antihypertensive",
      "index_drug_class": "INSTI",
      "index_drugs_examples": ["dolutegravir", "bictegravir", "raltegravir"],
      "ade_mechanism_es": "Mecanismo no completamente establecido; posiblemente relacionado con recuperación inmune y efectos metabólicos del INSTI",
      "ade_mechanism_en": "Mechanism not fully established; possibly related to immune recovery and INSTI metabolic effects",
      "ade_es": "Ganancia de peso significativa, síndrome metabólico, diabetes tipo 2",
      "ade_en": "Significant weight gain, metabolic syndrome, type 2 diabetes",
      "cascade_drug_class": "Antidiabetic / Antihypertensive / Lipid-lowering",
      "cascade_drugs_examples": ["metformin", "sitagliptin", "liraglutide", "enalapril", "atorvastatin"],
      "plausibility": "medium",
      "time_to_ade_typical_days_min": 90,
      "time_to_ade_typical_days_max": 730,
      "evidence_level": "B",
      "ddi_warning_es": "Dolutegravir aumenta los niveles de metformina (~2-3x). Usar con precaución; valorar reducción de dosis de metformina.",
      "ddi_warning_en": "Dolutegravir increases metformin levels (~2-3x). Use with caution; consider reducing metformin dose.",
      "clinical_note_es": "Evaluar si el cambio del INSTI a otro ARV puede revertir la ganancia de peso antes de añadir más medicamentos cardiometabólicos.",
      "clinical_note_en": "Evaluate if switching INSTI to another ARV can reverse weight gain before adding more cardiometabolic drugs.",
      "references": ["Venter WDF et al. N Engl J Med 2019", "Bourgi K et al. Clin Infect Dis 2020"]
    },
    {
      "id": "VIH004",
      "name_es": "Efavirenz (EFV) → Síntomas SNC → Hipnótico/Antidepresivo/Ansiolítico",
      "name_en": "Efavirenz (EFV) → CNS Symptoms → Hypnotic/Antidepressant/Anxiolytic",
      "index_drug_class": "NNRTI",
      "index_drugs_examples": ["efavirenz"],
      "ade_mechanism_es": "Efecto agonista del receptor cannabinoide CB1 y actividad en receptores GABA/NMDA → síntomas neuropsiquiátricos",
      "ade_mechanism_en": "CB1 cannabinoid receptor agonism and GABA/NMDA receptor activity → neuropsychiatric symptoms",
      "ade_es": "Insomnio, sueños vívidos/pesadillas, mareos, depresión, ansiedad, deterioro cognitivo",
      "ade_en": "Insomnia, vivid dreams/nightmares, dizziness, depression, anxiety, cognitive impairment",
      "cascade_drug_class": "CNS drug",
      "cascade_drugs_examples": ["zolpidem", "lorazepam", "mirtazapine", "sertraline", "fluoxetine", "amitriptyline"],
      "plausibility": "high",
      "time_to_ade_typical_days_min": 1,
      "time_to_ade_typical_days_max": 180,
      "evidence_level": "A",
      "ddi_warning_es": "CUIDADO: Efavirenz induce CYP3A4 → puede reducir niveles de muchos medicamentos psiquiátricos. Verificar interacciones específicas.",
      "ddi_warning_en": "CAUTION: Efavirenz induces CYP3A4 → may reduce levels of many psychiatric medications. Verify specific interactions.",
      "clinical_note_es": "Los síntomas SNC de EFV suelen mejorar en 2-4 semanas. Considerar cambio a otro NNRTI (rilpivirina, doravirina) o INSTI antes de añadir medicación psiquiátrica.",
      "clinical_note_en": "EFV CNS symptoms usually improve in 2-4 weeks. Consider switching to another NNRTI (rilpivirine, doravirine) or INSTI before adding psychiatric medication.",
      "references": ["Clifford DB et al. Neurology 2005", "Apostolova N et al. AIDS 2015"]
    },
    {
      "id": "VIH005",
      "name_es": "IP/r → Síntomas GI (náuseas/diarrea) → Antidiarreico/Antiemético",
      "name_en": "PI/r → GI Symptoms (nausea/diarrhea) → Antidiarrheal/Antiemetic",
      "index_drug_class": "Boosted PI",
      "index_drugs_examples": ["lopinavir/ritonavir", "darunavir/ritonavir", "atazanavir/cobicistat", "darunavir/cobicistat"],
      "ade_mechanism_es": "Irritación GI directa del ritonavir/cobicistat, efectos sobre motilidad intestinal",
      "ade_mechanism_en": "Direct GI irritation from ritonavir/cobicistat, effects on intestinal motility",
      "ade_es": "Diarrea, náuseas, vómitos, flatulencia, dolor abdominal",
      "ade_en": "Diarrhea, nausea, vomiting, flatulence, abdominal pain",
      "cascade_drug_class": "Antidiarrheal / Antiemetic",
      "cascade_drugs_examples": ["loperamide", "ondansetron", "metoclopramide", "domperidone"],
      "plausibility": "high",
      "time_to_ade_typical_days_min": 1,
      "time_to_ade_typical_days_max": 60,
      "evidence_level": "B",
      "clinical_note_es": "Considerar si el IP actual puede cambiarse por uno con mejor tolerabilidad GI (p.ej., darunavir tiene mejor perfil que LPV/r).",
      "clinical_note_en": "Consider whether current PI can be switched to one with better GI tolerability (e.g., darunavir has better profile than LPV/r).",
      "references": ["Calza L et al. HIV Med 2003"]
    },
    {
      "id": "VIH006",
      "name_es": "Atazanavir → Hiperbilirrubinemia → Evaluación/Tratamiento ictericia",
      "name_en": "Atazanavir → Hyperbilirubinemia → Jaundice evaluation/Treatment",
      "index_drug_class": "PI",
      "index_drugs_examples": ["atazanavir", "atazanavir/ritonavir", "atazanavir/cobicistat"],
      "ade_mechanism_es": "Inhibición de UGT1A1 → acumulación de bilirrubina indirecta → ictericia esclerótica",
      "ade_mechanism_en": "UGT1A1 inhibition → indirect bilirubin accumulation → scleral icterus",
      "ade_es": "Hiperbilirrubinemia indirecta, ictericia, cálculos biliares",
      "ade_en": "Indirect hyperbilirubinemia, jaundice, gallstones",
      "cascade_drug_class": "Investigación adicional / Tratamiento hepatobiliar",
      "cascade_drugs_examples": ["ursodeoxycholic acid"],
      "plausibility": "high",
      "time_to_ade_typical_days_min": 14,
      "time_to_ade_typical_days_max": 90,
      "evidence_level": "A",
      "clinical_note_es": "La hiperbilirrubinemia por atazanavir es benigna (sin daño hepatocelular). No requiere tratamiento pero puede causar ictericia visible. Cambio a otro IP o INSTI si es molesto.",
      "clinical_note_en": "Atazanavir hyperbilirubinemia is benign (no hepatocellular damage). Does not require treatment but can cause visible jaundice. Switch to another PI or INSTI if bothersome.",
      "references": ["Sulkowski MS et al. Ann Intern Med 2004"]
    },
    {
      "id": "VIH007",
      "name_es": "ARV (especialmente TDF/TDF-IP/r) → Osteopenia/Osteoporosis → Bisfosfonato/Calcio/Vitamina D",
      "name_en": "ARV (especially TDF/TDF-PI/r) → Bone Loss → Bisphosphonate/Calcium/Vitamin D",
      "index_drug_class": "ART",
      "index_drugs_examples": ["tenofovir disoproxil fumarate", "lopinavir/ritonavir", "any ART"],
      "ade_mechanism_es": "TDF → disfunción tubular renal → pérdida de fosfato → osteomalacia/pérdida ósea. IP/r → alteración del metabolismo de vitamina D.",
      "ade_mechanism_en": "TDF → renal tubular dysfunction → phosphate loss → osteomalacia/bone loss. PI/r → vitamin D metabolism alteration.",
      "ade_es": "Disminución de densidad mineral ósea, osteoporosis, fracturas",
      "ade_en": "Decreased bone mineral density, osteoporosis, fractures",
      "cascade_drug_class": "Bone protective agents",
      "cascade_drugs_examples": ["alendronate", "risedronate", "zoledronic acid", "calcium carbonate", "cholecalciferol", "calcitriol"],
      "plausibility": "medium",
      "time_to_ade_typical_days_min": 180,
      "time_to_ade_typical_days_max": 1825,
      "evidence_level": "B",
      "clinical_note_es": "Suplementación con calcio y vitamina D puede ser apropiada. Para bisfosfonatos, verificar indicación formal con DEXA.",
      "clinical_note_en": "Calcium and vitamin D supplementation may be appropriate. For bisphosphonates, verify formal indication with DEXA.",
      "references": ["Brown TT et al. Clin Infect Dis 2015", "BHIVA Guidelines 2023"]
    },
    {
      "id": "VIH008",
      "name_es": "Zidovudina (AZT) → Anemia/Mielotoxicidad → Eritropoyetina/Transfusión",
      "name_en": "Zidovudine (AZT) → Anemia/Myelotoxicity → Erythropoietin/Transfusion",
      "index_drug_class": "NRTI",
      "index_drugs_examples": ["zidovudine", "AZT"],
      "ade_mechanism_es": "Inhibición de timidina cinasa mitocondrial → supresión de médula ósea → anemia macrocítica",
      "ade_mechanism_en": "Mitochondrial thymidine kinase inhibition → bone marrow suppression → macrocytic anemia",
      "ade_es": "Anemia macrocítica, neutropenia, mielotoxicidad",
      "ade_en": "Macrocytic anemia, neutropenia, myelotoxicity",
      "cascade_drug_class": "Hematopoietic growth factors / Iron / Vitamins",
      "cascade_drugs_examples": ["epoetin alfa", "darbepoetin", "filgrastim", "ferrous sulfate", "folic acid"],
      "plausibility": "high",
      "time_to_ade_typical_days_min": 30,
      "time_to_ade_typical_days_max": 180,
      "evidence_level": "A",
      "clinical_note_es": "AZT es cada vez menos usado en países de altos ingresos. Considerar cambio a ABC o TAF/TDF si la anemia es atribuible a AZT.",
      "clinical_note_en": "AZT is increasingly less used in high-income countries. Consider switching to ABC or TAF/TDF if anemia is attributable to AZT.",
      "references": ["Richman DD et al. N Engl J Med 1987"]
    }
  ],
  "art_interactions_notes": {
    "cyp3a4_inhibitors": {
      "drugs": ["ritonavir", "cobicistat"],
      "note_es": "Ritonavir y cobicistat son potentes inhibidores de CYP3A4. Pueden elevar significativamente los niveles de muchos medicamentos co-administrados, creando cascadas por toxicidad de medicamentos normalmente seguros.",
      "note_en": "Ritonavir and cobicistat are potent CYP3A4 inhibitors. They can significantly raise levels of many co-administered drugs, creating cascades via toxicity of normally safe medications."
    },
    "cyp3a4_inducers": {
      "drugs": ["efavirenz", "nevirapine", "etravirine", "rifampicin"],
      "note_es": "Los NNRTIs (especialmente EFV/NVP) y la rifampicina son inductores de CYP3A4. Pueden reducir los niveles de medicamentos co-administrados, llevando a fracaso terapéutico y potencialmente a prescripción de dosis más altas o medicamentos adicionales.",
      "note_en": "NNRTIs (especially EFV/NVP) and rifampicin are CYP3A4 inducers. They can reduce levels of co-administered drugs, potentially leading to therapeutic failure and prescribing of higher doses or additional medications."
    }
  }
}
